Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375641![]() (US9908897, Example 21) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.776 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375697![]() (US9908897, Example 75) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.32 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375651![]() (US9908897, Example 37) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.38 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375716![]() (US9908897, Example 92) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.45 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375686![]() (US9908897, Example 65) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.62 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375717![]() (US9908897, Example 93 | US9908897, Example 94) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.04 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375709![]() (US9908897, Example 87) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.14 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375644![]() (US9908897, Example 25) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.19 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375640![]() (US9908897, Example 19) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.29 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375652![]() (US9908897, Example 38) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.45 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375722![]() (US9908897, Example 98) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.57 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent serotonin transporter (Homo sapiens (Human)) | BDBM375649![]() (US9908897, Example 35) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.55 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375717![]() (US9908897, Example 93 | US9908897, Example 94) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.63 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375639![]() (US9908897, Example 17) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.80 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375675![]() (US9908897, Example 56) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.80 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375720![]() (US9908897, Example 96 | US9908897, Example 97) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.89 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375696![]() (US9908897, Example 74) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.17 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375631![]() (US9908897, Example 8 | US9908897, Example 9) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.17 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375636![]() (US9908897, Example 13) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.17 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375714![]() (US9908897, Example 90) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.37 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375642![]() (US9908897, Example 23) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.79 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375660![]() (US9908897, Example 44) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.13 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375687![]() (US9908897, Example 66) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.13 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375631![]() (US9908897, Example 8 | US9908897, Example 9) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.62 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375669![]() (US9908897, Example 50) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.75 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375674![]() (US9908897, Example 55) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.46 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375649![]() (US9908897, Example 35) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.92 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375719![]() (US9908897, Example 95) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.92 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375710![]() (US9908897, Example 88) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.08 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375704![]() (US9908897, Example 82) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.24 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375623![]() (US9908897, Example 1 | US9908897, Example 2) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.24 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375699![]() (US9908897, Example 77) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.32 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375684![]() (US9908897, Example 63) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.51 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375662![]() (US9908897, Example 46) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.33 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375683![]() (US9908897, Example 62) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.77 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375659![]() (US9908897, Example 43) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.77 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375680![]() (US9908897, Example 59) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.77 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375715![]() (US9908897, Example 91) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.77 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent serotonin transporter (Homo sapiens (Human)) | BDBM375704![]() (US9908897, Example 82) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375723![]() (US9908897, Example 102) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375623![]() (US9908897, Example 1 | US9908897, Example 2) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375720![]() (US9908897, Example 96 | US9908897, Example 97) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 11.2 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375706![]() (US9908897, Example 84) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 11.5 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375700![]() (US9908897, Example 78) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 11.5 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375676![]() (US9908897, Example 57) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 12.9 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375701![]() (US9908897, Example 79) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 13.8 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375688![]() (US9908897, Example 67) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 15.8 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375713![]() (US9908897, Example 89) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 18.6 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent serotonin transporter (Homo sapiens (Human)) | BDBM375627![]() (US9908897, Example 5) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 23.4 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Sodium-dependent dopamine transporter (Homo sapiens (Human)) | BDBM375661![]() (US9908897, Example 45) | NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 25.7 | n/a | n/a | n/a | n/a | n/a | n/a |
CHRONOS THERAPEUTICS LIMITED US Patent | Assay Description The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine... | US Patent US9908897 (2018) BindingDB Entry DOI: 10.7270/Q2P55QTW | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 306 total ) | Next | Last >> |